

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS F O Box 1450 Alexandria, Virginia 22313-1450 www.uspilo.gov

45733 7590 04/10/2008 EXAMINER LEYDIG, VOIT & MAYER, L'ITD. 17WO PRUDENTIAL IP IAZA, SUITE 4900 180 NORTH STETSON AVENUE CHICAGO, IL 60601-6731 1648	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
LEYDIG, VOIT & MAYER, LTD. TWO PRUDENTIAL PLAZA, SUITE 4900 180 NORTH STETSON AVENUE CHICAGO, IL 60601-6731 1648 LE EMILY M ART UNIT PAPER N 1648	09/720,276	03/07/2001	John W. Erickson	207596	9981	
TWO PRUDENTIAL PLAZA, SUITE 4900 180 NORTH STETSON AVENUE CHICAGO, IL 60601-6731 LE, IMILY M ART UNIT PAPER N 1648			EXAM	EXAMINER		
CHICAGO, IL 60601-6731 ART UNIT PAPER N 1648	TWO PRUDE	NTIAL PLAZA, SUITI	LE, EMILY M			
			ART UNIT	PAPER NUMBER		
MAIL DATE DELIVER				1648	1648	
MAIL DATE DELIVER						
04/10/2008 PAI					DELIVERY MODE PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
09/720,276	ERICKSON ET AL.	
Examiner	Art Unit	
Emily Le	1648	

	Emily Le	1648				
The MAILING DATE of this communication appe	ars on the cover sheet with the	correspondence add	ress			
THE REPLY FILED 25 March 2008 FAILS TO PLACE THIS AP	PLICATION IN CONDITION FOR	ALLOWANCE.				
 X The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance, (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C pendos: 	the same day as filing a Notice of replies: (1) an amendment, affidavi- cal (with appeal fee) in compliance FR 1.114. The reply must be filed	Appeal. To avoid abar t, or other evidence, w with 37 CFR 41.31; or	vhich places the r (3) a Request			
a) The period for reply expires	dvisory Action, or (2) the date set forth ater than SIX MONTHS from the mailin b). ONLY CHECK BOX (b) WHEN THE	g date of the final rejection	on.			
Extensions of time may be obtained under 37 CFR 1.136(a). The date whave been filled is the date for purposes of determining the period of ext under 37 CFR 1.17(a) is calculated from: (1) the expiration date of thes set forth in (b) above, if checked. Any reply received by the Office later may reduce any earmed patient term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	ension and the corresponding amount hortened statutory period for reply origi than three months after the mailing dal	of the fee. The appropria nally set in the final Office	ate extension fee e action; or (2) as			
 The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed with 	sion thereof (37 CFR 41.37(e)), to	avoid dismissal of the				
AMENDMENTS						
 ∑ The proposed amendment(s) filed after a final rejection, t. (a) ∑ They raise new issues that would require further cor (b) ☐ They raise the issue of new matter (see NOTE belown of the properties of the pr	nsideration and/or search (see NO w);	ΓE below);				
(d) ☐ They present additional claims without canceling a c NOTE: See Continuation Sheet. (See 37 CFR 1.1)		ected claims.				
The amendments are not in compliance with 37 CFR 1.12 Applicant's reply has overcome the following rejection(s): Newly proposed or amended claim(s) would be all	21. See attached Notice of Non-Co	,	,			
non-allowable claim(s). No rep ruproses of appeal, the proposed amendment(s): a) the work the new or amended claims would be rejected is proved the status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 47 and 49-81.		l be entered and an ex	xplanation of			
Claim(s) withdrawn from consideration:						
AFFIDAVIT OR OTHER EVIDENCE 8. The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).						
 The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary 	vercome <u>all</u> rejections under appear and was not earlier presented. Se	al and/or appellant fail: se 37 CFR 41.33(d)(1	s to provide a).			
 The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER 	n of the status of the claims after e	ntry is below or attach	ed.			
11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because:						
12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s) 13. Other:						
/E.L./	/Emily Le/ Patent Examiner, Art Ur	nit 1648				

Continuation of 3. NOTE: It should be kept in mind that applicant cannot, as a matter of right, amend any finally rejected claims, add new claims after a final rejection (see 3 of ZFR.116) or reinstate previously canceled claims. Except where an year man continuation claims, adopts examiner suggestions, removes issues for appeal, or in some other way requires only a cursory review by the examiner, compliance with the requirement of a showing under 37 CFR.1116(b)(3) is expected in all amendments after final rejection.

The proposed amendment does not merely cancels claims, adopts examiner suggestions, removes issues for appeal nor in some way requires only a cursory review by the examiner. The proposed amendment raises new issues that would require further search for the proposed amendment contains claims that differ significant from the examined claims. The examined claims are directed to a method of inhibiting the development of drug resistance in an HIV infected animal with the administration of a composition; whereas, the proposed amendments est forth a different invention, a method of treating an HIV infected animal that has developed resistance to HIV treatment with various active method steps. Due to the noted difference, the entry of the proposed amendment would necessitate further search. Therefore, the entry of the amendment is defined.